[Federal Register Volume 79, Number 133 (Friday, July 11, 2014)]
[Notices]
[Pages 40113-40114]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-16207]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0894]


2014 Scientific Meeting of the National Antimicrobial Resistance 
Monitoring System; Public Meeting; Request for Comments

AGENCY: Food and Drug Administration, HHS.

[[Page 40114]]


ACTION: Notice of public meeting; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing a public 
meeting entitled ``2014 Scientific Meeting of the National 
Antimicrobial Resistance Monitoring System.'' The purpose of the 
meeting is to discuss progress made in achieving the goals of the 
National Antimicrobial Resistance Monitoring System (NARMS) Strategic 
Plan: 2012-2016.
    Dates And Time: The public meeting will be held on August 12 and 
13, 2014, from 8 a.m. to 5 p.m.

ADDRESSES: Location: The public meeting will be held at the FDA White 
Oak Campus, 10903 New Hampshire Ave., Building 31, Great Room (rm. 
1503A), Silver Spring, MD 20993-0002. Please note that visitors to the 
White Oak Campus must enter through Building 1. The White Oak Campus 
location is a Federal facility with security procedures. For parking 
and security information, please refer to http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.

FOR FURTHER INFORMATION CONTACT: Laura Bradbard, Center for Veterinary 
Medicine (HFV-12), Food and Drug Administration, 7519 Standish Pl., 
Rockville, MD 20855, 240-276-9109, FAX: 240-276-9115, 
laura.bradbard@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: NARMS periodically conducts public meetings 
to inform stakeholders of NARMS activities and receive comments on ways 
to improve. The last two public NARMS meetings (held in 2010 and 2011) 
focused on recommendations made by the FDA Science Board Advisory 
Subcommittee in 2007. These meetings dealt with enhancing international 
partnerships, and improving NARMS sampling. Since then, NARMS created 
the 2012-2016 Strategic Plan that addressed all of the Science Board's 
recommendations (http://www.fda.gov/downloads/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/UCM236283.pdf). A 
number of strategic planning goals already have been achieved and 
several of the objectives outlined in the plan are ongoing. The purpose 
of this meeting will be to provide updates on progress of the NARMS 
2012-2016 strategic plan, discuss possible future activities, and 
receive comments for the official record. A number of items will be 
discussed including comparisons of new and old slaughter sampling 
methods, the role of NARMS in foodborne outbreaks, results of 
interagency research projects using advanced detection methods, and how 
these scientific advances impact FDA decisionmaking.
    Registration and Requests for Oral Presentations: Interested 
persons may make oral presentations on the topic of the discussion of 
the meeting. Oral presentations from the public during the open public 
comment period will be scheduled between approximately 3:50 p.m. and 
4:50 p.m. on August 13, 2014. Those desiring to make oral presentations 
should notify the contact person by July 29, 2014, and submit a brief 
statement of the general nature of information they wish to present. In 
an effort to accommodate all who desire to speak, time allotted for 
each presentation may be limited. The contact person will inform each 
speaker of their schedule prior to the meeting.
    Registration is required for the meeting. Please send registration 
information (including name, title, organization, address, and 
telephone and fax numbers) by email to Laura Bradbard (see FOR FURTHER 
INFORMATION CONTACT) by July 29, 2014. There is no fee to register for 
the public meeting, and registration will be on a first-come, first-
served basis.
    If you need special accommodations due to a disability, please 
contact Laura Bradbard (see FOR FURTHER INFORMATION CONTACT) at least 7 
days in advance.
    Comments: Regardless of attendance at the public meeting, 
interested persons may submit either electronic or written comments 
regarding the topic to be discussed at the meeting. Submit electronic 
comments to http://www.regulations.gov. Submit written comments to the 
Division of Dockets Management (HFA-305), Food and Drug Administration, 
5630 Fishers Lane, rm. 1061, Rockville, MD 20852. It is only necessary 
to send one set of comments. Identify comments with the docket number 
found in brackets in the heading of this document. Received comments 
may be seen in the Division of Dockets Management between 9 a.m. and 4 
p.m., Monday through Friday. The docket will remain open for written or 
electronic comments for 30 days following the meeting.
    Agenda: The meeting will address monitoring and research for NARMS. 
The final agenda for the public meeting will be made available on the 
Agency's Web site at http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/ucm059135.htm and will 
be posted to the docket athttp://www.regulations.gov no later than 2 
weeks prior to the meeting.
    Transcripts: FDA will prepare a meeting transcript and make it 
available on the Agency's Web site (see Agenda) after the meeting. FDA 
anticipates that transcripts will be available approximately 60 
business days after the meeting. The transcript will be available for 
public examination at the Division of Dockets Management (HFA-305), 
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, 
MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. A 
transcript will also be available in either hardcopy or on CD-ROM after 
submission of a Freedom of Information request. Written requests are to 
be sent to Division of Freedom of Information (ELEM-1029), Food and 
Drug Administration, 12420 Parklawn Dr., Element Bldg., Rockville, MD 
20857.

    Dated: July 7, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-16207 Filed 7-10-14; 8:45 am]
BILLING CODE 4164-01-P